Switching from Sotalol to Flecainide
Before switching from sotalol to flecainide, you must first confirm the patient has no structural heart disease, no coronary artery disease, no heart failure, and no significant left ventricular hypertrophy—flecainide is absolutely contraindicated in these populations due to increased mortality risk. 1, 2, 3
Eligibility Criteria
Mandatory Requirements for Flecainide Use:
- No structural heart disease (normal left ventricular function)
- No coronary artery disease or ischemic heart disease
- No heart failure (especially HFrEF with LVEF ≤40%)
- No significant left ventricular hypertrophy (wall thickness <1.4 cm)
- No intraventricular conduction delay, particularly left bundle branch block
- Baseline QRS duration <120 msec 1, 2, 3
Additional Contraindications:
- Brugada syndrome
- Sinus or AV node dysfunction without pacemaker
- Recent myocardial infarction
- Baseline QTc >450 msec 4, 3
If any of these conditions exist, do not switch to flecainide—consider amiodarone or dronedarone instead. 1, 5
Washout Period
Implement a 2-3 plasma half-life washout period for sotalol before initiating flecainide. 6
- Sotalol half-life: 12 hours (normal renal function)
- Minimum washout: 48-72 hours (2-3 half-lives)
- Adjust for renal impairment: Sotalol is renally eliminated, so patients with CrCl <60 mL/min require longer washout periods (up to 5-7 days) 7
During Washout:
- Monitor QTc interval—ensure it returns to <450 msec before starting flecainide 4, 7
- Check serum potassium and magnesium—correct any deficiencies
- Maintain rate control with beta-blockers, diltiazem, or verapamil if needed
- Continue anticoagulation per CHA₂DS₂-VASc score 8, 3
Flecainide Initiation Protocol
Baseline Assessment:
- ECG: Confirm QRS <120 msec, QTc <450 msec, no bundle branch block
- Echocardiogram: Verify normal LVEF, no LVH, no structural disease
- Renal function: Calculate creatinine clearance (flecainide requires dose adjustment if CrCl <35 mL/min)
- Electrolytes: Potassium and magnesium within normal range 1, 8
Dosing:
Start flecainide 50 mg twice daily, then titrate to 100 mg twice daily after 3-4 days if tolerated. Maximum dose is 150 mg twice daily (300 mg/day total). 1, 2
- Initial dose: 50 mg PO BID
- After 3-4 days: Increase to 100 mg PO BID
- Maximum: 150 mg PO BID (if needed for efficacy)
Critical Monitoring During Initiation:
Obtain ECG 2-4 hours after each dose increase and monitor QRS duration—if QRS widens by ≥25% from baseline or exceeds 150 msec, reduce dose or discontinue immediately. 1, 4
- Day 1-3: ECG at baseline and 2-4 hours post-dose
- After dose increase: Repeat ECG monitoring
- QRS widening >25%: Reduce dose or stop drug
- QRS >150 msec: Stop drug 1
Mandatory Concomitant AV Nodal Blockade
Always prescribe a beta-blocker, diltiazem, or verapamil with flecainide to prevent 1:1 AV conduction if atrial flutter develops. 1, 4
Flecainide can convert atrial fibrillation to atrial flutter with rapid ventricular conduction (potentially 1:1), which is life-threatening. AV nodal blocking agents prevent this complication.
Ongoing Monitoring
- ECG every 3-6 months: Check QRS duration
- Exercise testing: Consider if patient exercises regularly, as use-dependent QRS widening occurs at faster heart rates 6
- Renal function: Monitor if baseline CrCl <60 mL/min
- Symptoms: Educate patient to report syncope, palpitations, or dizziness immediately 1, 9
Common Pitfalls to Avoid
- Never use flecainide in patients with any degree of structural heart disease—this was associated with increased mortality in the CAST trial
- Never initiate without AV nodal blockade—risk of 1:1 atrial flutter conduction
- Never skip the washout period—overlapping sotalol and flecainide increases proarrhythmic risk
- Never ignore QRS widening—this predicts ventricular proarrhythmia 1, 4, 10
Alternative if Flecainide is Contraindicated
If structural heart disease, CAD, or HF is present: